E-LIB Suche - Ergebnisse für: Shimazaki, Ryutaro

1

Neutralizing-antibody-independent SARS-CoV-2 control correl..:

Ishii, Hiroshi ; Nomura, Takushi ; Yamamoto, Hiroyuki...
Cell Reports Medicine. 3 (2022) 2 - p. 100520 , 2022

Link: https://doi.org/10.1016/..

2

Development of intranasal Sendai virus vector-based vaccine..:

SHIMAZAKI, Ryutaro ; KUSANO, Kohji
Translational and Regulatory Sciences. 3 (2021) 3 - p. 122-124 , 2021

Link: https://doi.org/10.33611..

3

Correction to: Efficacy and safety of evocalcet in Japanese..:

Evocalcet Study Group ; Tsuruya, Kazuhiko ; Shimazaki, Ryutaro..
Clinical and Experimental Nephrology. 23 (2019) 9 - p. 1173-1173 , 2019

Link: https://doi.org/10.1007/..

4

Response to Comments on "Pharmacokinetics, Pharmacodynamics..:

Evocalcet Study Group ; Akizawa, Tadao ; Shimazaki, Ryutaro..
Clinical Drug Investigation. 39 (2019) 1 - p. 109-111 , 2019

Link: https://doi.org/10.1007/..

5

Long-Term Efficacy and Safety of Evocalcet in Japanese Pati..:

Yokoyama, Keitaro ; Shimazaki, Ryutaro ; Fukagawa, Masafumi...
Scientific Reports. 9 (2019) 1 - p. , 2019

Link: https://doi.org/10.1038/..

6

Efficacy and safety of evocalcet in Japanese peritoneal dia..:

Tsuruya, Kazuhiko ; Shimazaki, Ryutaro ; Fukagawa, Masafumi...
Clinical and Experimental Nephrology. 23 (2019) 6 - p. 739-748 , 2019

Link: https://doi.org/10.1007/..

7

An open-label, randomized, phase 3 study of the efficacy an..:

the Antithrombin Gamma Study Group ; Endo, Shigeatsu ; Shimazaki, Ryutaro
Journal of Intensive Care. 6 (2018) 1 - p. , 2018

Link: https://doi.org/10.1186/..

8

Nrf2 activator for the treatment of kidney diseases:

Yamawaki, Kengo ; Kanda, Hironori ; Shimazaki, Ryutaro
Toxicology and Applied Pharmacology. 360 (2018) - p. 30-37 , 2018

Link: https://doi.org/10.1016/..

9

Pharmacokinetics, Pharmacodynamics, and Safety of the Novel..:

Evocalcet Study Group ; Akizawa, Tadao ; Shimazaki, Ryutaro..
Clinical Drug Investigation. 38 (2018) 10 - p. 945-954 , 2018

Link: https://doi.org/10.1007/..

10

Phase 2b study of evocalcet (KHK7580), a novel calcimimetic..:

Akizawa, Tadao ; Shimazaki, Ryutaro ; Fukagawa, Masafumi..
PLOS ONE. 13 (2018) 10 - p. e0204896 , 2018

Link: https://doi.org/10.1371/..

11

First‐in‐Asian Phase I Study of the Anti‐Fibroblast Growth ..:

Cheong, Hae Il ; Yoo, Han‐Wook ; Adachi, Masanori...
JBMR Plus. 3 (2018) 2 - p. , 2018

Link: https://doi.org/10.1002/..

12

Head-to-head comparison of the new calcimimetic agent evoca..:

Fukagawa, Masafumi ; Shimazaki, Ryutaro ; Akizawa, Tadao
Kidney International. 94 (2018) 4 - p. 818-825 , 2018

Link: https://doi.org/10.1016/..

13

Pharmacokinetics of evocalcet in secondary hyperparathyroid..:

Shigematsu, Takashi ; Shimazaki, Ryutaro ; Fukagawa, Masafumi.
Clinical Pharmacology: Advances and Applications. 10 (2018) - p. 101-111 , 2018

Link: https://doi.org/10.2147/..

14

Assessment of CYP‐Mediated Drug Interactions for Evocalcet,..:

Narushima, Kazuya ; Maeda, Hiroshi ; Shiramoto, Masanari...
Clinical and Translational Science. 12 (2018) 1 - p. 20-27 , 2018

Link: https://doi.org/10.1111/..

15

Pharmacodynamics of evocalcet for secondary hyperparathyroi..:

Evocalcet Study Group ; Shigematsu, Takashi ; Shimazaki, Ryutaro..
Clinical and Experimental Nephrology. 23 (2018) 2 - p. 258-267 , 2018

Link: https://doi.org/10.1007/..